Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Real-time Estimate Cboe BZX Other stock markets 03:15:28 2024-05-10 pm EDT			5-day change	1st Jan Change
1.425 ^USD	-8.65%		-12.80%	-80.54%

May. 07	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 07	GL
Immuneering Recognizes Melanoma Awareness Month	May. 06	GL
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	Apr. 09	GL
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Mar. 27	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Mar. 27	AQ
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	Mar. 20	AQ
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	Mar. 14	GL
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	Mar. 14	AQ
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	Mar. 12	GL
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	Mar. 12	AQ
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	Mar. 11	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	Mar. 05	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	Mar. 05	AQ
Immuneering to Participate in the Cowen 44th Annual Health Care Conference	Mar. 04	GL
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	Mar. 01	GL
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	Feb. 20	GL
Immuneering Announces Participation in February Investor Conferences	Feb. 01	GL
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Dec. 12	GL
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Dec. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Press Releases

Filters